Izquierdo, AndreaCubero Gallego, HéctorAparisi, ÁlvaroVaquerizo Montilla, BeatrizRibas Barquet, Núria2022-11-022022-11-022022Izquierdo-Marquisá A, Cubero-Gallego H, Aparisi Á, Vaquerizo B, Ribas-Barquet N. Myocardial injury in COVID-19 and its implications in short- and long-term outcomes. Front Cardiovasc Med. 2022 May 26; 9: 901245. DOI: 10.3389/fcvm.2022.9012452297-055Xhttp://hdl.handle.net/10230/54643COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a pandemic with high mortality and morbidity rates. Clinical manifestation is widely variable, including asymptomatic or mild respiratory tract illness to severe pneumonia and death. Myocardial injury is a significant pathogenic feature of COVID-19 and it is associated with worse in-hospital outcomes, mainly due to a higher number of hospital readmissions, with over 50% mortality. These findings suggest that myocardial injury would identify COVID-19 patients with higher risk during active infection and mid-term follow-up. Potential contributors responsible for myocardial damage are myocarditis, vasculitis, acute inflammation, type 1 and type 2 myocardial infarction. However, there are few data about cardiac sequelae and its long-term consequences. Thus, the optimal screening tool for residual cardiac sequelae, clinical follow-up, and the benefits of a specific cardiovascular therapy during the convalescent phase remains unknown. This mini-review explores the different mechanisms of myocardial injury related to COVID-19 and its short and long-term implications.application/pdfengCopyright © 2022 Izquierdo-Marquisá, Cubero-Gallego, Aparisi, Vaquerizo and Ribas-Barquet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) http://creativecommons.org/licenses/by/4.0/. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.info:eu-repo/semantics/articlehttp://dx.doi.org/10.3389/fcvm.2022.901245COVID-19SARS CoV-2BiomarkersInfectionInflammationOrgan failurePrognosisinfo:eu-repo/semantics/openAccess